Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Declines By 55.6%

Posted by Eileen French on Mar 28th, 2025

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 2,400 shares, a decrease of 55.6% from the February 28th total of 5,400 shares. Based on an average daily volume of 6,700 shares, the short-interest ratio is currently 0.4 days.

Santen Pharmaceutical Price Performance

SNPHY stock opened at $9.63 on Friday. The firm has a 50-day moving average of $9.59 and a 200 day moving average of $10.69. Santen Pharmaceutical has a 1 year low of $8.65 and a 1 year high of $13.00.

Santen Pharmaceutical Company Profile

(Get Free Report)

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.